In this study, the authors first used an AlphaScreen assay to identify a series of tryptophan-based cyclic peptide compounds with FXR-antagonistic activity, specifically those modified with a ...
This study was published online in the Journal of Hepatology. By establishing a diet-induced MASH model, researchers found that hepatocyte-specific knockout of βKlotho significantly blocked the ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
The study investigated the effects of Thykamineâ„¢ on liver disease progression in the widely used STAM mouse model of MASH/fibrosis at SMC Laboratories in Japan. In this model, diabetic mice were ...
with MASH-related cirrhosis, Child-Pugh class A, and model for end-stage liver disease scores ≤10. Among those, 62 underwent metabolic surgery (37 Roux-en-Y gastric bypass and 25 sleeve ...
39% of patients in the 50mg EFX group demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, a significant finding with a p-value of 0.009 compared to placebo. Data suggests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback